PLEASE VISIT AMPLITY.COM TO LEARN WHY THE LYNX GROUP AND AMPLITY ARE BETTER TOGETHER
PM360_Trailblazer_2019   EDDIE_OZZIE_HM   PM360_Elite_2020   EDDIE_OZZIE_Winner   PM360_Trailblazer_2020   Inc_5000   PM360_Trailblazer_2021

Amyloidosis News to Present Disease State Education on ATTR-CM

January 5, 2022

CRANBURY, N.J., Jan. 5, 2022 - Amyloidosis News, an educational resource for healthcare providers who treat patients with heart failure, is pleased to present the third program of its popular “Master Class Series on Transthyretin Amyloid Cardiomyopathy (ATTR-CM).”

This master class series, consisting of 5 half-hour virtual programs, is designed to provide disease state education on ATTR-CM, which is a rare, life-threatening, underrecognized, and underdiagnosed type of amyloidosis that is associated with heart failure.

The third program, titled “Tools to Diagnose and Monitor ATTR-CM,” will be held at 12 p.m. on January 18, 2022. This program will feature a roundtable discussion with expert panelists on the diagnostic and prognostic tools that are utilized to help guide treatment decisions for ATTR-CM.

Attendees will have an opportunity to participate in a live Q&A with the panelists after each session. Panelists for this program include:

  • David Fermin, MD, FACC, FHFSA, Spectrum Health
  • Ike Okwuosa, MD, Northwestern Feinberg School of Medicine
  • David Wolinsky, MD, FACC, MASNC, Cleveland Clinic

This master class series is supported by BridgeBio, a US-based public company that focuses on the development of medicines for genetic diseases.

In the first 2 programs of this series, experts discussed the impact of ATTR cardiomyopathy on patients’ physical health and quality of life, and the significance and potential clinical implications of maximal TTR stabilization in ATTR.

To sign up for the third program or watch recordings of the first 2 programs, visit the Amyloidosis News website: https://amyloidosisnews.com/master-class-series.

About Amyloidosis News

Amyloidosis News is an educational resource for healthcare providers who treat patients with heart failure to promote early diagnosis and improved treatment outcomes in patients with cardiac amyloidosis. The Amyloidosis News platform will feature topics related to the key aspects of cardiac amyloidosis, offering original research, best practices (for diagnosis, risk assessment/staging, prognosis, management, and long-term follow-up), interviews with experts, interesting case reports, highlights of new study findings, medical conference-focused news, and more.

About The Lynx Group

The Lynx Group (TLG) is a premier medical communications and education company acutely focused on oncology and rare disease states. TLG specializes in market access to and with advanced practice providers, patients, and their caregivers. With more than 100 years of combined senior leadership experience, TLG continually creates award-winning medical education and cultivates strong relationships within proprietary brands serving patients and their caregivers, physicians, payers, nurses, pharmacists, navigators, and practice managers.

TLG has broad and deep experience in crafting custom, award-winning solutions for life science and biotech companies. Currently, TLG partners with more than 50 of the top pharma and biotech companies globally. TLG proudly serves as co-founder and association management company of the Academy of Oncology Nurse & Patient Navigators (AONN+) and the Association for Value-Based Cancer Care (AVBCC).

Last modified: December 23, 2021
  732-992-1880
 1249 South River Road, Suite 202A, Cranbury, NJ 08512
© The Lynx Group, LLC. All Rights Reserved.